Targovax’s ONCOS-102 receives FDA fast track designation for malignant pleural mesothelioma treatment
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted ... Read More
Siemens Healthineers to acquire cancer care technologies developer Varian Medical Systems
Siemens Healthineers acquisition of Varian Medical Systems : Germany-based Siemens Healthineers has signed an all-cash deal worth around $16.4 billion to acquire US-based cancer care ... Read More
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination ... Read More
Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture ... Read More
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference
MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy ... Read More
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn
US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per ... Read More
Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly ... Read More
Bexion Pharmaceuticals advances BXQ-350 cancer drug trial with phase 1 part 3 launch
Bexion Pharmaceuticals has launched part 3 of its phase 1 clinical trial for BXQ-350, an investigational cancer treatment aimed at advancing the fight against solid ... Read More
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical's ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV ... Read More